For media enquiries, please contact email@example.com
Conyers Dill & Pearman provided Cayman Islands legal advice to the Special Committee in connection with ShangPharma Corporation’s US$173 million privatisation by way of merger with ShangPharma Holdings Limited (“Holdings”), ShangPharma Parent Limited (“Parent”) and ShangPharma Merger Sub Limited (“Merger Sub”). As a result of the merger, the Company became a wholly owned subsidiary of Parent.
ShangPharma Corporation (NYSE: SHP) is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. The Company’s services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services.
Partner and Co-Chairman David Lamb and Associate Angie Chu of Conyers’ Hong Kong office advised on the matter working alongside O’Melveny & Meyers and Skadden, Arps, Slate, Meagher & Flom.